Indivior’s application for its new schizophrenia treatment has received approval from the U.S. Food and Drug Administration.
The British drugmaker, which specializes in heroin addiction treatment, said the FDA had accepted its application for RBP-7000, an investigational once-a-month injectable to treat schizophrenia.
The company’s experimental drug to fight opioid addiction was approved by the FDA earlier this month, boosting the company's sales prospects.
Read the Reuters report